Comparison of adverse effects of anti-tumor therapy for breast cancer shortly after COVID-19 diagnosis vs. the control period

BACKGROUND: COVID-19 is an acute infectious disease caused by SARS-CoV-2. The best time to restart antitumor therapy in breast cancer patients after SARS-CoV-2 infection is unknown. This study aimed to evaluate treatment-related adverse events in breast cancer patients who received antitumor therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Mao, Xiang, Hongyu, Ye, Jingming, Cheng, Yuanjia, Liu, Qian, Xu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475930/
https://www.ncbi.nlm.nih.gov/pubmed/37671052
http://dx.doi.org/10.3389/fonc.2023.1203119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475930/
https://www.ncbi.nlm.nih.gov/pubmed/37671052
http://dx.doi.org/10.3389/fonc.2023.1203119

Ejemplares similares